RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS.
Journal Information
Full Title: Acta Neuropathol
Abbreviation: Acta Neuropathol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Conflict of interestGGT, EZ, AP, MH are listed as inventors on a patent relating to the use of TDP-43 binding RNA aptamers: “WO2023217742—TDP-43-BINDING SINGLE-STRANDED APTAMERS AND USES THEREOF” (PCT/EP2023/062203). The authors declare no other conflicts of interest. Conflict of interest GGT, EZ, AP, MH are listed as inventors on a patent relating to the use of TDP-43 binding RNA aptamers: “WO2023217742—TDP-43-BINDING SINGLE-STRANDED APTAMERS AND USES THEREOF” (PCT/EP2023/062203). The authors declare no other conflicts of interest."
"Funding Target ALS, BB-2022-C4-L2, Mathew Horrocks, NIH, R01NS127186, Jenna M. Gregory, HORIZON EUROPE European Research Council, RIBOMYLOME_309545, Gian Tartaglia, ASTRA_855923, Gian Tartaglia."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025